A dual-label time-resolved fluorescence immunoassay for screening of osteoporosis based on simultaneous detection of C-terminal telopeptide (β-CTX) and aminoterminal propeptide (P1NP) of type I procollagen. (17th February 2019)

• Record Type: Journal Article
• Authors: Xu, Yichun; Wang, Qiyou; Hou, Gang; Yao, Hui; Zhao, Huiqing
• Is Part Of: Scandinavian journal of clinical & laboratory investigation. Volume 79:Number 1/2(2019)
• Page Start: 80
• Page End: 85
• Publication Date: 2019-02-17
• Subjects: Dual-label time-resolved fluorescence immunoassay -- C-terminal telopeptide -- aminoterminal propeptide -- osteoporosis -- detection; Clinical biochemistry -- Periodicals; Physiology, Pathological -- Periodicals; Physiology, Experimental -- Periodicals; Medicine -- Research -- Periodicals; Clinical medicine -- Periodicals; 616.0072
• DOI: 10.1080/00365513.2018.1555857
• Languages: English
• ISSNs: 0036-5513

Abstract

Abstract: Osteoporosis is a disease where increased bone weakness increases the risk of a broken bone. Until a broken bone occurs, there are typically no symptoms. Osteoporosis affects more than 75 million people in the United States, Europe and Japan. The diagnosis of osteoporosis is primarily determined by measuring bone mineral density using dual-energy X-ray absorptiometry, but for men under 50 years of age, premenopausal women should not be made on the basis of densitometric criteria alone. Bone biomarkers are a useful tool in detecting osteoporotic. A two-step dual-label time-resolved fluorescence immunoassay (TRFIA) was developed for the simultaneous detection of serum C-terminal telopeptide (β-CTX) and amino-terminal propeptide (P1NP) of Type I procollagen in a single run. The performance of this assay was first evaluated using clinical serum samples, and then compared with commercialized kits. The sensitivity of this assay for β-CTX was 1 ng/L (dynamic range, 0–1000 ng/L), and the sensitivity for P1NP detection was 1 μg/L (dynamic range, 1–1000 μg/L). High correlation coefficients ( R ) were obtained between the present dual-label TRFIA and commercially available kits ( R = 0.99 for β-CTX and P1NP). The present dual-label TRFIA has high sensitivity, specificity and accuracy in clinical sample analysis. It is a good alternative to the single-label diagnostic methods.